TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05833867
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).
Study: NCT05380271
Drug: sequential DEB-BACE and Arotinib and Tirelizumab
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DEB-BACE+Arotinib + Tirelizumab
Study: NCT05380271
Drug: DEB-BACE alone
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DEB-BACE alone
Study: NCT04839367
Drug: 64Cu-SAR-bisPSMA
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64Cu-SAR-bisPSMA
Study: NCT05290194
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
Study: NCT05233163
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10 mg oral daily for 12 weeks
Study: NCT05435170
Drug: linerixibat
Normalized name: LINERIXIBAT
DrugBank: Linerixibat (DB11729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: linerixibat will be administered per the treatment sequence
Study: NCT05288127
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered.
Study: NCT05840510
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRAS G12C inhibitor
Study: NCT05840510
Drug: nab-Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: mTOR inhibitor
Study: NCT05843188
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-Inflammatory - antimalarial - aminoquinolines
Study: NCT05843188
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antineoplastic agent
Study: NCT05843188
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antineoplastic agent
Study: NCT04900350
Drug: AK117
Normalized name: Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer
DrugBank: Ligufalimab (DB17542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive AK117 intravenously.
Study: NCT04900350
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects receive Azacitidine subcutaneously.
Study: NCT06543303
Drug: BTV100 Low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1% Cevimeline Ophthalmic Solution
Study: NCT06543303
Drug: BTV100 High dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Cevimeline Ophthalmic Solution
Study: NCT05835986
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Study: NCT04910568
Drug: Cevostamab
Normalized name: Cevostamab
DrugBank: Cevostamab (DB18374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
Study: NCT04910568
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Study: NCT04910568
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered orally (PO) on a 28-day cycle.
Study: NCT04910568
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
Study: NCT04910568
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product.
Study: NCT04980885
Drug: AK117
Normalized name: Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer
DrugBank: Ligufalimab (DB17542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive AK117 intravenously.
Study: NCT04980885
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects receive Azacitidine subcutaneously.
Study: NCT05934071
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: optimization of the medical therapy for heart failure with reduced ejection fraction with SGLT2 inhibitor, according to clinical guidelines
Study: NCT05340621
Drug: OKI-179 + binimetinib
Normalized name: OKI-179
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D.
Study: NCT05119569
Drug: Fenebrutinib
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib will be administered orally.
Study: NCT00002012
Drug: Interferon alfa-n3
Normalized name: Interferon alfa-n3
DrugBank: Interferon alfa-n3 (DB00018)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04753437
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin capsules.
Study: NCT04753437
Drug: Bismuth potassium citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth potassium citrate tablets.
Study: NCT04753437
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole tablets.
Study: NCT04753437
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan tablets.
Study: NCT05242042
Drug: JT001
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
Study: NCT05087134
Drug: 11C-Choline
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-Choline were injected into the patients before the PET/CT scans
Study: NCT06480760
Drug: Carnosine
Normalized name: Carnosine
DrugBank: Carnosine (DB11695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food ingredient (supplement)
Study: NCT06017895
Drug: doxepin solution
Normalized name: doxepin Oral Solution
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.0 mL doxepin solution (5mg/mL) sprayed to the posterior pharyngeal wall
Study: NCT05364190
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
Study: NCT05364190
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
Study: NCT05119439
Drug: Mifepristone + 2 doses of misoprostol 800 mcg
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
Study: NCT05526521
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection solution Subcutaneous
Study: NCT05784779
Drug: GH509
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once daily before bedtime (qhs)
Study: NCT05847205
Drug: r-Hirudin
Normalized name: R-hirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
Study: NCT05286593
Drug: Slow Infusion of Rubidium-82
Normalized name: 82 rubidium
DrugBank: Rubidium (DB11346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion
Study: NCT05286593
Drug: Slow Infusion of Rubidium-82
Normalized name: 82 rubidium
DrugBank: Rubidium (DB11346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion
Study: NCT05286593
Drug: Slow Infusion of Rubidium-82
Normalized name: 82 rubidium
DrugBank: Rubidium (DB11346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion
Study: NCT05286957
Drug: adjuvant tislelizumab and chemotherapy for MRD+ patients
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)
Study: NCT05286957
Drug: adjuvant tislelizumab and chemotherapy for MRD+ patients
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status
Study: NCT05286957
Drug: adjuvant chemotherapy for MRD- patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
Study: NCT06293053
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Injection solution~Route of administration: Subcutaneous
Study: NCT05561764
Drug: Imipenem/Cilastatin/Relebactam
Normalized name: imipenem/cilastatin/relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.
Study: NCT05159219
Drug: Colchicine Pill
Normalized name: colchicine Pill
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-inflammatory
Study: NCT05817812
Drug: Efanesoctocog alfa
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Study: NCT04819100
Drug: Selpercatinib
Normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT06088420
Drug: intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .
Study: NCT06253923
Drug: Amantadine Hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).
Study: NCT05455619
Drug: Evexomostat
Normalized name: Evexomostat
DrugBank: Evexomostat (DB19140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
Study: NCT03554707
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/m2/dose IV daily for five days in a 4-week cycle
Study: NCT03554707
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/m2 PO daily for five days in a 4-week cycle
Study: NCT03554707
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/kg IV every two weeks in a 4-week cycle
Study: NCT04762953
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal Paclitaxel
Study: NCT04762953
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Paclitaxel
Study: NCT05069896
Drug: Mirikizumab Prefilled Syringe
Normalized name: mirikizumab Prefilled Syringe
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC by prefilled syringe
Study: NCT05069896
Drug: Mirikizumab Autoinjector
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC by autoinjector
Study: NCT05735639
Drug: Dalteparin Sodium
Normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin
Study: NCT05735639
Drug: Tinzaparin Sodium
Normalized name: Tinzaparin Sodium
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin
Study: NCT05735639
Drug: Enoxaparin Sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low molecular weight heparin
Study: NCT05735639
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Direct oral anticoagulant
Study: NCT05735639
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Direct oral anticoagulant
Study: NCT05735639
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Direct oral anticoagulant
Study: NCT05807932
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study treatment consists of the conditioning therapy including 6 or 8 days of Venetoclax treatment.
Study: NCT05807932
Drug: Amsacrine
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
Study: NCT05807932
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ara-C is part of the conditioning therapy and is administered on day -10 to -7 before allogeneic blood stem cell transplantation
Study: NCT05807932
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
Study: NCT05807932
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil is used for prophylaxis of acute and chronic graft-versus-host-disease according to institutional standards.
Study: NCT00097383
Drug: ALIMTA plus Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04777357
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05789173
Drug: Methadone and Tizanidine
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
Study: NCT05789173
Drug: Efavirenz, Methadone and Tizanidine
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
Study: NCT05776524
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
Study: NCT05776524
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
Study: NCT03516968
Drug: Monthly bolus of cholecalciferol per os
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus therapy (100'000 - 200'000 IU/month depending on age: \< or ≥ 9 years old) for 3 months
Study: NCT03516968
Drug: Daily dose of cholecalciferol per os
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily substitution (3'500 to 6'500 IU/day depending on age: \< or ≥ 9 years old) for 3 months
Study: NCT06303284
Drug: subcutaneous Teriparatide injection
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 µg subcutaneous (SC) Teriparatide injection
Study: NCT04939649
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.
Study: NCT04939649
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
Study: NCT05251181
Drug: Centhaquine
Normalized name: Centhaquine
DrugBank: Centhaquine (DB16122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
Study: NCT05526118
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
Study: NCT06084481
Drug: ABBV-400
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06376396
Drug: albendazole and praziquantel
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination of albendazole plus praziquantel
Study: NCT06376396
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole alone
Study: NCT05472259
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin